Enanta Pharma (ENTA) Misses Q4 EPS by 20c
Tweet
Share
E-mailGet Alerts ENTA Hot Sheet
Join SI Premium – FREE
Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.36), $0.20 worse than the analyst estimate of ($1.16). Revenue for the quarter came in at $14.61 million versus the consensus estimate of $17.99 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VNET Group (VNET) Misses Q2 EPS by 164c
- H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)
- Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
